NCT05748171 2026-02-03A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLPfizerPhase 2 Recruiting100 enrolled
NCT05645718 2025-10-07Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaM.D. Anderson Cancer CenterPhase 2 Recruiting27 enrolled